7 Critical FDA Decisions Shaping Drug Access and Leadership in 2025

The U.S. Food and Drug Administration has made two major moves this week that could reshape the landscape of weight-loss treatments and the agency's regulatory leadership. From a controversial proposal to limit compounded versions of blockbuster obesity drugs to a sudden change in the head of its biologics center, these developments carry significant implications for patients, pharmaceutical companies, and public health. Here are seven key things you need to know about these unfolding stories.

1. FDA Targets Compounded Weight-Loss Drugs

The FDA has proposed excluding semaglutide and tirzepatide—the active ingredients in Novo Nordisk's Wegovy/Ozempic and Eli Lilly's Mounjaro/Zepbound—from the list of substances that large compounding facilities can use for mass production. The agency determined there is no “clinical need” for these compounders to produce large quantities of these medications, citing legal requirements that such compounding should only fill gaps when brand-name drugs are in shortage. This marks a significant shift after years of debate over the role of compounding in making these popular drugs more accessible.

2. A Victory for Novo Nordisk and Eli Lilly

The decision is a clear win for the two pharmaceutical giants, which have been battling against compounders who created cheaper, unapproved versions of their drugs. The companies argued that these copycats undermined their patents and posed safety risks. The FDA's proposal reinforces their market exclusivity and could reduce competition from lower-cost alternatives. However, it may also limit access for patients who relied on compounded versions due to insurance hurdles or supply shortages.

3. What This Means for Consumer Access

For consumers, the proposal could mean a return to tighter supply for weight-loss and diabetes medications. During the recent shortage crisis, many patients turned to compounded semaglutide and tirzepatide when brand-name drugs were unavailable. If the proposal becomes final, those options will vanish, leaving patients to navigate insurance coverage or pay high out-of-pocket costs. The FDA's rationale—that these drugs are no longer in shortage—may not account for regional disparities or affordability issues, sparking concerns among patient advocacy groups.

4. FDA Leadership Shake-Up at CBER

In a separate but equally consequential move, the FDA named Katherine Szarama as acting director of the Center for Biologics Evaluation and Research (CBER), which oversees vaccines, gene therapies, and blood products. Szarama, who joined the agency in late 2024 as deputy director, replaces Vinay Prasad after his abrupt departure. The change injects uncertainty into the regulation of cutting-edge biologics at a time when the center is reviewing several high-profile gene therapies and next-generation vaccines.

5. The Controversial Tenure of Vinay Prasad

Vinay Prasad left the FDA after a tumultuous period marked by contentious decisions on rare-disease drugs and vaccine policies. Commissioner Marty Makary announced in March that Prasad would return to the University of California, San Francisco. Observers note that Prasad's tenure was polarizing: he pushed for faster approvals but also faced criticism from patient groups and industry insiders. His exit opens questions about the direction of CBER's regulatory philosophy, especially under the current administration.

6. Katherine Szarama Steps into the Spotlight

Szarama, a seasoned regulator with a background in biologics oversight, now leads CBER on an acting basis. It is unclear whether she will be appointed permanently. Industry sources previously suggested that Houman Hemmati—an ophthalmologist, biopharma executive, and frequent Fox News commentator—was a top candidate for the role. Szarama's immediate priorities include smoothing the transition, addressing vaccine regulatory backlog, and ensuring continuity in gene therapy reviews. Her leadership style is expected to be more collaborative than Prasad's.

7. Looking Ahead: What These Changes Signal

Together, these two stories reveal a regulatory agency in flux. The compounding decision asserts the FDA's authority to protect brand-name drug markets while raising access concerns. The leadership change at CBER introduces uncertainty but also an opportunity for recalibration. For stakeholders—from patients to investors—these developments underscore the importance of monitoring FDA policy shifts that can dramatically alter the pharmaceutical landscape. Stay tuned as both proposals and appointments move through the formal process.

The coming weeks will bring further clarity: the compounding proposal is open for public comment, and the permanent CBER director search continues. For now, the FDA has sent clear signals about its priorities—protecting intellectual property and ensuring regulatory stability—even as it navigates internal transitions. Whether these moves ultimately benefit or hinder public health remains to be seen, but one thing is certain: the decisions made now will echo for years in the world of drug regulation.